Literature DB >> 9972118

Safety and efficacy of sub-antimicrobial-dose doxycycline therapy in patients with adult periodontitis.

S Ciancio1, R Ashley.   

Abstract

The objectives of the studies presented here were to assess the safety and efficacy of the adjunctive administration of sub-antimicrobial-dose doxycycline (SDD) for the treatment of adult periodontitis and to confirm the optimal dosing regimen. The studies summarized included four double-blind, placebo-controlled, randomized clinical trials, conducted over a period of 9 to 12 months. Analysis of efficacy data demonstrated that adjunctive SDD treatment resulted in: (1) increases in clinical attachment levels; (2) decreases in probing pocket depths; and (3) reductions in bleeding on probing in patients with adult periodontitis. There were no significant adverse events or unwanted long-term antimicrobial effects associated with orally administered SDD. The results of these clinical trials indicate that the adjunctive use of SDD 20 mg BID is an effective and well-tolerated regimen which can significantly improve several indices of periodontal health.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9972118     DOI: 10.1177/08959374980120011501

Source DB:  PubMed          Journal:  Adv Dent Res        ISSN: 0895-9374


  16 in total

1.  The effect of locally delivered doxycycline as an adjunctive therapy to scaling and root planing in smokers.

Authors:  Hassan Al Hulami; Nadir Babay; Fatin Awartani; Sukumaran Anil
Journal:  Saudi Dent J       Date:  2011-05-03

2.  Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo.

Authors:  Gilson C N Franco; Mikihito Kajiya; Tadashi Nakanishi; Kouji Ohta; Pedro L Rosalen; Francisco C Groppo; Cory W O Ernst; Janie L Boyesen; John D Bartlett; Philip Stashenko; Martin A Taubman; Toshihisa Kawai
Journal:  Exp Cell Res       Date:  2011-03-21       Impact factor: 3.905

3.  Pharmacokinetics of doxycycline in adults with cystic fibrosis.

Authors:  Paul M Beringer; Heather Owens; Albert Nguyen; Debbie Benitez; Adupa Rao; David Z D'Argenio
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

4.  Subantimicrobial dose doxycycline effects on alveolar bone loss in post-menopausal women.

Authors:  Jeffrey B Payne; Julie A Stoner; Pirkka V Nummikoski; Richard A Reinhardt; Arthur D Goren; Mark S Wolff; Hsi-Ming Lee; James C Lynch; Robert Valente; Lorne M Golub
Journal:  J Clin Periodontol       Date:  2007-09       Impact factor: 8.728

5.  Effect of systemic matrix metalloproteinase inhibition on periodontal wound repair: a proof of concept trial.

Authors:  R Gapski; J L Barr; D P Sarment; M G Layher; S S Socransky; W V Giannobile
Journal:  J Periodontol       Date:  2004-03       Impact factor: 6.993

Review 6.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

Review 7.  Host-response therapeutics for periodontal diseases.

Authors:  William V Giannobile
Journal:  J Periodontol       Date:  2008-08       Impact factor: 6.993

8.  Subantimicrobial dose doxycycline effects on osteopenic bone loss: microbiologic results.

Authors:  Clay Walker; Susan Puumala; Lorne M Golub; Julie A Stoner; Richard A Reinhardt; Hsi-Ming Lee; Jeffrey B Payne
Journal:  J Periodontol       Date:  2007-08       Impact factor: 6.993

9.  Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine.

Authors:  Ying Gu; Clay Walker; Maria E Ryan; Jeffrey B Payne; Lorne M Golub
Journal:  J Oral Microbiol       Date:  2012-10-12       Impact factor: 5.474

10.  Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease.

Authors:  Esther Nalini Honibald; Sebeena Mathew; Jeyantha Padmanaban; Elanchezhiyan Sundaram; Renuka Devi Ramamoorthy
Journal:  J Pharm Bioallied Sci       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.